23 April 2021 | News
Malaysia’s hub will be part of AstraZeneca’s A.Catalyst Network, bringing together digital, R&D and commercial resources to improve patient outcomes
Image credit- shutterstock.com
AstraZeneca has entered into a new partnership with Malaysia based Sunway University via its innovation arm, Sunway Innovation Labs (Sunway iLabs), to establish the first Health Innovation Hub (HIH) in Malaysia.
The Hub is part of the AstraZeneca A.Catalyst Network, an interconnected global network of more than 20 AstraZeneca health innovation hubs.
In line with the Malaysian government’s call for digital innovation in the health care sector, the Hub will empower local start-ups and innovators to deliver new, sustainable solutions which will bolster the treatment of non-communicable diseases (NCDs) and support the patient experience, starting at the primary-care level.
The partnership was formalised by a Memorandum of Understanding (MoU) signing ceremony between both parties and was witnessed by guests of honour Dr Hishamshah Ibrahim, Deputy Director General, Health (Research & Technical Support), Ministry of Health and Dag Juhlin-Dannfelt, Ambassador of Sweden. Khairy Jamaluddin, Minister of Science, Technology, and Innovation delivered the keynote address virtually at the event.
Malaysia’s hub will be part of AstraZeneca’s A.Catalyst Network, bringing together digital, R&D and commercial resources to improve patient outcomes. The Malaysia hub is the tenth hub launched in Emerging Markets, together with the hubs located in Russia, Brazil, Argentina, India, Singapore and Gulf Cooperation Council (GCC) countries, as well as mainland China, Taiwan and Hong Kong.
Through the A.Catalyst Network, AstraZeneca is co-creating challenge-based solutions with and for patients, and working with partners to establish integrated healthcare systems that benefit the whole patient experience — from prevention and awareness, diagnosis and treatment to post-treatment and wellness.